Hsp90特异性抑制剂对HeLa宫颈癌细胞p53蛋白表达的影响

发布时间：2018-05-31 14:29

本文选题：靶向组蛋白去乙酰化酶抑制剂 + 宫颈癌hela细胞　；参考：《基因组学与应用生物学》2017年05期

【摘要】：HSP90抑制剂作为新型抗肿瘤药物,其治疗肿瘤效果良好,是目前抗肿瘤新药研发的热点。本研究目的在于探讨Hsp90特异性抑制剂对宫颈癌hela细胞增殖、凋亡影响及其调节p53通路的作用机制。利用HSP90抑制剂干预宫颈癌hela细胞24 h、48 h、72 h后细胞生长抑制率情况,观察HSP90抑制剂作用宫颈癌hela细胞48 h后细胞凋亡及半胱氨酸蛋白酶-3(Caspase-3)、半胱氨酸蛋白酶-8(Caspase-8)及p53蛋白水平变化的影响。结果表明,HSP90抑制剂可导致宫颈癌hela细胞形态学改变,增加细胞通透性,破坏细胞膜导致细胞破碎脱落。HSP90抑制剂能有效抑制宫颈癌hela细胞,可抑制细胞增殖并促进宫颈癌hela细胞凋亡,且呈剂量及时间依赖性。在细胞培养48 h后随HSP90抑制剂浓度增加,Caspase-3、Caspase-8、p53表达显著增加。结果表明HSP90抑制剂能可通过上调Caspase-3、Caspase-8、p53蛋白表达而诱导宫颈癌hela细胞凋亡。
[Abstract]:As a new anti-tumor drug, HSP90 inhibitor has a good effect on tumor and is a hot spot in the research and development of new anti-tumor drugs. The aim of this study was to investigate the effects of Hsp90 specific inhibitors on the proliferation and apoptosis of cervical cancer hela cells and the mechanism of regulating p53 pathway. HSP90 inhibitor was used to interfere with the growth inhibition rate of cervical cancer hela cells after 24 h, 48 h and 72 h. The effects of HSP90 inhibitor on apoptosis of hela cells and the changes of Caspase-3, Caspase-8 and p53 protein levels were observed. The results showed that HSP90 inhibitor could induce morphological changes of cervical carcinoma hela cells, increase cell permeability, and destroy cell membrane, resulting in cell fragmentation and shedding. HSP90 inhibitor could effectively inhibit cervical cancer hela cells. It can inhibit cell proliferation and promote apoptosis of cervical cancer hela cells in a dose and time dependent manner. After 48 hours of culture, the expression of Caspase-3, Caspase-8 and p53 increased with the concentration of HSP90 inhibitor. The results showed that HSP90 inhibitor could induce apoptosis of cervical cancer hela cells by up-regulating the expression of Caspase-3, caspase-8 and p53 protein.
【作者单位】：唐山工人医院;
【基金】：唐山工人医院资助
【分类号】：R737.33

【相似文献】